A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

This study has been terminated.
(A planned interim analysis was performed after approx. 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00389519
First received: October 17, 2006
Last updated: June 6, 2012
Last verified: June 2012

October 17, 2006
June 6, 2012
October 2006
November 2007   (final data collection date for primary outcome measure)
Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Blood pressure measured in the principal investigator's clinic before and after 4 weeks of treatment.
Complete list of historical versions of study NCT00389519 on ClinicalTrials.gov Archive Site
  • Change From Baseline to 4 Weeks in Trough Sitting Diastolic Blood Pressure [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]
    Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
  • Change From Baseline to 4 Weeks in Serum Creatinine [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
    Value at end of treatment (up to 4 weeks) minus value at baseline
  • Change From Baseline to 4 Weeks in Serum Potassium [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
    Value at end of treatment (up to 4 weeks) minus value at baseline
  • Change From Baseline to 4 Weeks in Schwartz Formula Glomerular Filtration Rate (GFR) [ Time Frame: Baseline up to 4 weeks ] [ Designated as safety issue: Yes ]
    Value at end of treatment (up to 4 weeks) minus value at baseline; GFR is a measure of kidney function.
Safety (adverse events and selected laboratory tests)
Not Provided
Not Provided
 
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Information is needed on the treatment of hypertension in children and adolescents with antihypertensive drugs like ramipril. The study will assess the safety and blood pressure effects of several doses of the antihypertensive drug ramipril in children and adolescents age 6-16 years. Approximately 450 children will be given placebo, or 1 of the 3 doses of ramipril. The treatment assigned will be done by chance, like flipping a coin. Approximately 120 study centers throughout the world will participate in the trial.

Each child will complete a 1- to 4-week Screening Period where they will stop taking their current blood pressure lowering drug(s), a 4-week Treatment Period where they will receive placebo or one of the ramipril doses, and a Follow-up visit 1 week after completion of the Treatment Period. Children diagnosed with hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (U.S. report), will be included in the study if their blood pressure meets certain values.

Each child will complete a minimum of 6 and up to 9 clinic visits over the course of the study during which procedures and assessments of blood pressure and safety will be performed. In addition, a child's parents/guardians will be instructed to measure their child's blood pressure at home between clinic visits.

A planned interim analysis was performed after approximately 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypertension
  • Drug: ramipril
    once a day oral ramipril capsules given for 4 weeks
    Other Name: Altace
  • Drug: placebo
    once a day oral placebo capsule for 4 weeks
  • Placebo Comparator: Placebo
    once per day
    Intervention: Drug: placebo
  • Experimental: ramipril low dose
    0.3125, 0.625, or 1.25 mg once a day, based on subject weight
    Intervention: Drug: ramipril
  • Experimental: ramipril mid dose
    1.25, 2.5, or 5 mg once a day, based on subject weight
    Intervention: Drug: ramipril
  • Experimental: ramipril high dose
    5, 10, or 20 mg once a day, based on subject weight
    Intervention: Drug: ramipril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
422
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
  2. The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
  3. The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
  4. Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
  5. Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria:

  1. Bilateral renal artery stenosis.
  2. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
  3. Severe hypertension.
  4. Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
  5. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
  6. A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
  7. Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
  8. History of pancreatitis (active or inactive).
  9. Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.
Both
6 Years to 16 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Chile,   Colombia,   India,   Poland,   South Africa,   Turkey,   Ukraine
 
NCT00389519
K726-06-4003
Not Provided
Not Provided
Pfizer
Not Provided
Not Provided
Pfizer
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP